dc.contributor.author | Harmand, Thibault | |
dc.contributor.author | Islam, Md Ashraful | |
dc.contributor.author | Pishesha, Novalia | |
dc.contributor.author | Ploegh, Hidde L. | |
dc.date.accessioned | 2022-03-07T08:21:00Z | |
dc.date.available | 2022-03-07T08:21:00Z | |
dc.date.issued | 2021-03-08 | |
dc.description.abstract | In vivo imaging has become in recent years an incredible tool to study biological events and has found
critical applications in diagnostic medicine. Although a lot of efforts and applications have been
achieved using monoclonal antibodies, other types of delivery agents are being developed. Among
them, VHHs, antigen binding fragments derived from camelid heavy chain–only antibodies, also known
as nanobodies, have particularly attracted attention. Indeed, their stability, fast clearance, good tissue
penetration, high solubility, simple cloning and recombinant production make them attractive targeting
agents for imaging modalities such as PET, SPECT or Infra-Red. In this review, we discuss the pioneering
work that has been carried out using VHHs and summarize the recent developments that have been
made using nanobodies for in vivo, non-invasive, imaging. | en_US |
dc.identifier.citation | Harmand, Islam A, Pishesha, Ploegh HL. Nanobodies as in vivo, non-invasive,
imaging agents RSC Chemical Biology. 2021, 2, 685 | en_US |
dc.identifier.cristinID | FRIDAID 1897478 | |
dc.identifier.doi | 10.1039/D1CB00023C | |
dc.identifier.issn | 2633-0679 | |
dc.identifier.uri | https://hdl.handle.net/10037/24280 | |
dc.language.iso | eng | en_US |
dc.publisher | Royal Society of Chemistry | en_US |
dc.relation.journal | RSC Chemical Biology | |
dc.rights.accessRights | openAccess | en_US |
dc.rights.holder | Copyright 2021 The Author(s) | en_US |
dc.title | Nanobodies as in vivo, non-invasive,
imaging agents | en_US |
dc.type.version | publishedVersion | en_US |
dc.type | Journal article | en_US |
dc.type | Tidsskriftartikkel | en_US |
dc.type | Peer reviewed | en_US |